Impact of cirrhosis on patients admitted with an exacerbation of acute chronic obstructive pulmonary disease: a nationwide analysis

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. The co-occurrence of COPD exacerbation and cirrhosis may compound clinical complexity and elevate adverse outcome risks. This study aimed to evaluate the impact of cirrhosis on outcomes among patients admitted with acute exacerbations of COPD. METHODS: Data were extracted from the Nationwide Inpatient Sample database for the period of 2019 to 2021. Patients hospitalized with acute exacerbations of COPD were identified using ICD-10 codes. The study population was stratified into patients with cirrhosis and those without. The primary outcome was in-hospital mortality. Secondary outcomes included sepsis, hepatic encephalopathy, respiratory failure, cardiac arrest, cardiac arrhythmias, pneumothorax, pulmonary embolism, acute kidney injury, and hospital length of stay. RESULTS: Among 914,498 patients hospitalized with COPD exacerbations, 4.2% had cirrhosis. Cirrhotic patients were younger and had higher in-hospital mortality, longer length of stay, and higher hospital charges compared to noncirrhotics. Cirrhosis was independently associated with increased mortality and a higher risk of sepsis, acute kidney injury, encephalopathy, shock, and prolonged hospitalization. Associations with arrhythmia and cardiac arrest were not statistically significant. CONCLUSION: Cirrhosis is associated with higher in-hospital mortality and increased risk of complications in patients admitted for COPD exacerbations, contributing to longer hospital stays and higher healthcare costs. Clinical monitoring and tailored management are warranted in this group.